tetano
Editor, Senior Moderator
Front Med (Lausanne)
. 2022 Mar 4;9:826247.
doi: 10.3389/fmed.2022.826247. eCollection 2022.
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
Saleh Al-Muhsen[SUP] 1 [/SUP], Nouf S Al-Numair[SUP] 2 [/SUP], Narjes Saheb Sharif-Askari[SUP] 3 [/SUP], Roaa Basamh[SUP] 4 [/SUP], Banan Alyounes[SUP] 4 [/SUP], Amjad Jabaan[SUP] 4 [/SUP], Fatemeh Saheb Sharif-Askari[SUP] 3 [/SUP], Mohammed F Alosaimi[SUP] 1 [/SUP], Fahad Alsohime[SUP] 1 [/SUP], Rabih Halwani[SUP] 1 3 5 [/SUP], Haya Al-Saud[SUP] 4 6 [/SUP]
Affiliations
Abstract
Objectives: There are limited data on the efficacy and safety of favipiravir antiviral in coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase. This study aims to evaluate the favipiravir effect on reducing the length of hospital stay and in-hospital mortality among moderate and severe hospitalized COVID-19 patients.
Methods: A prospective, multicenter observational study was conducted that included moderate and severe hospitalized adult COVID-19 patients in four major regions (Riyadh (Riyadh), Eastern (Dammam), Al-Qassem (Buraydah), and Macca (Jeddah) of Saudi Arabia. For the primary outcome of all-cause mortality, a Cox proportional hazard analysis was performed. While the association between favipiravir use and length of hospital stay was determined using adjusted generalized linear model. This study was approved by the Central Institutional Review Board in The Saudi Ministry of Health (MoH) with the approval number IRB # 20-85-M.
Results: This study included 598 moderate and severe COVID-19 patients, of whom 156 (26%) received favipiravir. Favipiravir treatment was associated with more extended hospital stays (14 vs. 10 median days, P = 0.034) and higher mortality rate (aHR 3.63; 95% CI 1.06-12.45) compared to no favipiravir regimen. Despite lack of effectiveness, favipiravir use was only associated with higher diarrhea adverse effects (12 vs. 5%, P = 0.002), but it did not affect the renal and liver profiles of patients.
Conclusion: Favipiravir was ineffective in reducing the length of hospital stay and in-hospital mortality in patients with moderate and severe COVID-19.
Keywords: COVID-19; SARS-CoV-2; favipiravir; in-hospital mortality; length of hospital stay.
. 2022 Mar 4;9:826247.
doi: 10.3389/fmed.2022.826247. eCollection 2022.
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
Saleh Al-Muhsen[SUP] 1 [/SUP], Nouf S Al-Numair[SUP] 2 [/SUP], Narjes Saheb Sharif-Askari[SUP] 3 [/SUP], Roaa Basamh[SUP] 4 [/SUP], Banan Alyounes[SUP] 4 [/SUP], Amjad Jabaan[SUP] 4 [/SUP], Fatemeh Saheb Sharif-Askari[SUP] 3 [/SUP], Mohammed F Alosaimi[SUP] 1 [/SUP], Fahad Alsohime[SUP] 1 [/SUP], Rabih Halwani[SUP] 1 3 5 [/SUP], Haya Al-Saud[SUP] 4 6 [/SUP]
Affiliations
- PMID: 35308532
- PMCID: PMC8931493
- DOI: 10.3389/fmed.2022.826247
Abstract
Objectives: There are limited data on the efficacy and safety of favipiravir antiviral in coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase. This study aims to evaluate the favipiravir effect on reducing the length of hospital stay and in-hospital mortality among moderate and severe hospitalized COVID-19 patients.
Methods: A prospective, multicenter observational study was conducted that included moderate and severe hospitalized adult COVID-19 patients in four major regions (Riyadh (Riyadh), Eastern (Dammam), Al-Qassem (Buraydah), and Macca (Jeddah) of Saudi Arabia. For the primary outcome of all-cause mortality, a Cox proportional hazard analysis was performed. While the association between favipiravir use and length of hospital stay was determined using adjusted generalized linear model. This study was approved by the Central Institutional Review Board in The Saudi Ministry of Health (MoH) with the approval number IRB # 20-85-M.
Results: This study included 598 moderate and severe COVID-19 patients, of whom 156 (26%) received favipiravir. Favipiravir treatment was associated with more extended hospital stays (14 vs. 10 median days, P = 0.034) and higher mortality rate (aHR 3.63; 95% CI 1.06-12.45) compared to no favipiravir regimen. Despite lack of effectiveness, favipiravir use was only associated with higher diarrhea adverse effects (12 vs. 5%, P = 0.002), but it did not affect the renal and liver profiles of patients.
Conclusion: Favipiravir was ineffective in reducing the length of hospital stay and in-hospital mortality in patients with moderate and severe COVID-19.
Keywords: COVID-19; SARS-CoV-2; favipiravir; in-hospital mortality; length of hospital stay.